Lithium | 1H'22 - higher for longer

Can 2022 eclipse 2021? 2022 is shaping up to be a stand out year in the lithium market, hard pressed given 2021 delivered impressive price rises across carbonate (431%), hydroxide (340%) and spodumene (532%). However, after refreshing our SxD model for EV sales and lithium production we do not see an easy route for the market to balance throughout the year. This is being reflected in spot pricing recently pushing over US$50,000/t. We anticipate this pressure being maintained over at least the first six months of 2022 before additional supply reaches the market. In this report, we update our price forecasts and price targets for our global lithium coverage.

Equities can keep going higher, but we are starting to look for opportunities: Lithium equities were strong performers in 2021, closing up on average +200% YoY. Into January the names continued to rally, following lithium pricing. We have upgraded our producer/near-term producers (NTP) 36% on average and developers 24% on average. Most equities are pricing in the recent moves with the producer/NTP trading at 0.82x P/NAV on average, vs developers trading at 0.66x P/NAV on average. We have downgraded PLS and INR to HOLD on valuation, both names remain topical however the equities are trading towards fair valuation. We are upgrading RCK to SPEC BUY (from HOLD) due to the recent pullback in the shares. See our key picks below.

Market balance - tight, but supply response will come: Our update focussed on rebasing our EV sales for 2021 and expected growth profile (9.5m units in 2022) and updating our lithium project pipeline. At current pricing we are more than 3x incentive pricing and projects are now getting financed, rather than companies looking to progress studies. Our balance to 2024 remains largely unchanged, with demand more or less matching supply. We continue to point to 2025 as a potential surplus year before heading into deficits out to 2030. A noticeable difference from our September report is the scale of deficits from 2026, which are smaller due to incremental supply.

Key risks to our modelled deficits are lower EV sales driven by chip or raw material shortages and higher production from existing assets which are brought on faster to satisfy customer demand. Another consideration is if raw material (and energy) pricing shortages and higher production from existing assets which are brought online faster to satisfy customer demand. Another consideration is if raw material (and energy) pricing pressure is sustained, or less matching supply. We continue to point to 2025 as a potential surplus year before heading into deficits out to 2030. A noticeable difference from our September report is the scale of deficits from 2026, which are smaller due to incremental supply.

Price forecasts - tight market but ultimately eases back towards LT pricing: We have lifted our price forecasts for SC6/Li2CO3/LiOH out to 2030 (Figure 17). We have lifted our 2022 pricing by 125% to US$3,425/t for SC6; 57% to US$43,125/t for Li2CO3 (FOB Sth America); and 37% to US$38,750/t for LiOH (Asia CIF). In response to rising capital intensities for lithium projects, our long term pricing (from 2026) has increased by 25% for SC6 to US$1,000/t, and chemicals 17% to US$17,500/t.

CG global lithium sector coverage - key picks

Producers - AKE-ASX, IGO-ASX

Developers - ALLA-AIM, SGML-TSXV, VUL-ASX, FFX-ASX (pending Leo Lithium demerger), LKE-ASX
A quick look in the rear-view mirror at 2021

2021 kicked off the lithium decade in an impressive way. Chemical and spodumene pricing ‘melted up’ over the year with spodumene 532% higher over the year, carbonate 431% higher and hydroxide 340% higher. Equities followed pricing with developers up 250% on average (albeit from lower bases) and the producers up 97%. PLS-ASX had a standout year and deservedly so. Introduction of its BMX auction platform has the potential to shift the balance of power in the lithium market. The first auctions have shown the level of desperation in the market by some participants, pushing pricing towards the point where, at spot, a converter would make no margins.

Driving demand was the EV sector, where we continually tried to play catch up as sales/deliveries consistently outdid our expectations. Although final numbers are not yet in, we anticipate sales of 6.2m units (+103% YoY) with 3.1m in China, 2.1m in Europe and 0.7m in the North America. On the supply front producers in Western Australia were able to lift production (Greenbushes, Pilbara) as did South American brine producers (Albemarle, SQM). However, with little available inventories and the majors not releasing volumes, those without captive supply were left to fight it out for feedstock tonnes.

While we witnessed some increase in sector consolidation during the first half of the year (Galaxy & Orocobre, IGO & Tianqi), it was the second half of the year where a ‘scramble for resources’ hit overdrive. Chinese companies Ganfeng and CATL were the most aggressive, taking out or buying into five projects in 2H’21, and spending a combined US$2bn in the process. Overall, we estimate a total of US$7bn was spent on M&A during 2021 up from US$400m compared with 2020.

2021 also saw Automotive OEMs and battery producers invest in a pipeline of battery manufacturing capacity. A notable announcement was Volkswagen’s commitment to build six 40GWh battery factories in Europe by 2030 (equates to ~350kt of LCE demand).

We published over 50 lithium-focussed notes including two S&D reviews and 12 initiations to take our coverage to 17 lithium focussed stocks globally.

Figure 1: Performance over 2021 for a selection of lithium products and CG covered lithium producers & developers

Source: Company reports, Canaccord Genuity estimates * Chemical prices (US$/t China EXW), Spodumene (US$/t Aus FOB).
Lithium | 1H’22 higher for longer

We have reviewed our SxD assumptions for 2021 and updated our price deck. In August 2021 we published 2H’21 recharge, where we brought forward expectations of market deficits and revised up our price forecasts, while in September 2021 an out of cycle price adjustment was required as pricing had increased by over 50% in a single month (see Lithium prices go exponential). This trend continued into the end of the year, with Chinese chemical prices up 200% and concentrate prices up 350% since our last update. Our key focus for this report was to rebase demand and assess the current supply response based on current pricing.

Price deck – key changes

Based on our revised modelling, we have lifted our peak pricing scenarios for both chemicals and concentrates. We have also lifted our long-term chemical price assumptions to US$17.5k/t for LC/LiOH on account of higher capital intensities and what it means for incentive pricing, and we lift LT concentrate prices by 25% to US$1,000/t align with our view on LT converter margins (Figure 17).

Revisions to modelled pricing see an average 27% increase in valuations/target prices for our lithium sector coverage, with changes outlined in Figure 2 below.

Figure 2: CG Global Lithium coverage – Summary of target price and recommendation changes

<table>
<thead>
<tr>
<th>Company</th>
<th>Code</th>
<th>Analyst</th>
<th>Price</th>
<th>Mkt Cap ($m)</th>
<th>Old TP</th>
<th>New TP</th>
<th>% Chng</th>
<th>P/NAV</th>
<th>New Rating</th>
<th>Prev. Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pilbara Minerals</td>
<td>PLS-ASX</td>
<td>Tim Hoff</td>
<td>$3.56</td>
<td>$10.597</td>
<td>$2.70</td>
<td>$3.90</td>
<td>44%</td>
<td>0.91</td>
<td>Hold</td>
<td>Buy</td>
</tr>
<tr>
<td>IGO Limited</td>
<td>IGO-ASX</td>
<td>Tim Hoff</td>
<td>$12.80</td>
<td>$9.693</td>
<td>$11.00</td>
<td>$15.00</td>
<td>36%</td>
<td>0.85</td>
<td>Buy</td>
<td>Buy</td>
</tr>
<tr>
<td>Aliken Limited</td>
<td>AKE-ASX</td>
<td>Reg Spencer</td>
<td>$10.35</td>
<td>$6.598</td>
<td>$12.00</td>
<td>$15.00</td>
<td>25%</td>
<td>0.69</td>
<td>Buy</td>
<td>Buy</td>
</tr>
<tr>
<td>Lithium Americas</td>
<td>LAC-CA</td>
<td>Katie Lachapelle</td>
<td>$31.56</td>
<td>$3794</td>
<td>$46.00</td>
<td>$54.00</td>
<td>17%</td>
<td>0.58</td>
<td>Spec Buy</td>
<td>Spec Buy</td>
</tr>
<tr>
<td>Liontown Resources</td>
<td>LTR-ASX</td>
<td>Reg Spencer</td>
<td>$1.62</td>
<td>$3.539</td>
<td>$1.90</td>
<td>$2.30</td>
<td>21%</td>
<td>0.70</td>
<td>Spec Buy</td>
<td>Spec Buy</td>
</tr>
<tr>
<td>Ioneer Ltd</td>
<td>INR-ASX</td>
<td>Tim Hoff</td>
<td>$0.74</td>
<td>$1.507</td>
<td>$0.75</td>
<td>$0.85</td>
<td>13%</td>
<td>0.87</td>
<td>Hold</td>
<td>Spec Buy</td>
</tr>
<tr>
<td>Core Lithium Ltd</td>
<td>CXO-ASX</td>
<td>Tim Hoff</td>
<td>$0.65</td>
<td>$1.415</td>
<td>$0.70</td>
<td>$1.00</td>
<td>43%</td>
<td>0.85</td>
<td>Spec Buy</td>
<td>Spec Buy</td>
</tr>
<tr>
<td>Standard Lithium</td>
<td>SLI-CA</td>
<td>Katie Lachapelle</td>
<td>$8.14</td>
<td>$1311</td>
<td>$14.00</td>
<td>$14.00</td>
<td>0%</td>
<td>0.58</td>
<td>Spec Buy</td>
<td>Spec Buy</td>
</tr>
<tr>
<td>Vulcan Energy</td>
<td>VUL-ASX</td>
<td>Tim Hoff</td>
<td>$9.42</td>
<td>$1.240</td>
<td>$2.01</td>
<td>$2.30</td>
<td>10%</td>
<td>0.41</td>
<td>Spec Buy</td>
<td>Spec Buy</td>
</tr>
<tr>
<td>Piedmont Lithium</td>
<td>PLL-ASX</td>
<td>Reg Spencer</td>
<td>$0.68</td>
<td>$1.029</td>
<td>$1.35</td>
<td>$1.55</td>
<td>15%</td>
<td>0.44</td>
<td>Spec Buy</td>
<td>Spec Buy</td>
</tr>
<tr>
<td>Sigma Lithium</td>
<td>SGML-CA</td>
<td>Katie Lachapelle</td>
<td>$11.97</td>
<td>$1.046</td>
<td>$14.00</td>
<td>$17.00</td>
<td>21%</td>
<td>0.70</td>
<td>Spec Buy</td>
<td>Spec Buy</td>
</tr>
<tr>
<td>Lake Resources</td>
<td>LKE-ASX</td>
<td>Reg Spencer</td>
<td>$0.94</td>
<td>$1.149</td>
<td>$1.15</td>
<td>$1.50</td>
<td>30%</td>
<td>0.63</td>
<td>Spec Buy</td>
<td>Spec Buy</td>
</tr>
<tr>
<td>Neo Lithium</td>
<td>NLC-CA</td>
<td>Katie Lachapelle</td>
<td>$6.42</td>
<td>$9070</td>
<td>$6.50</td>
<td>$6.50</td>
<td>0%</td>
<td>0.99</td>
<td>Hold</td>
<td>Hold</td>
</tr>
<tr>
<td>Firefinch Resources</td>
<td>FFX-ASX</td>
<td>Reg Spencer</td>
<td>$0.75</td>
<td>$884</td>
<td>$1.55</td>
<td>$1.90</td>
<td>23%</td>
<td>0.39</td>
<td>Spec Buy</td>
<td>Spec Buy</td>
</tr>
<tr>
<td>Galan Lithium</td>
<td>GLN-ASX</td>
<td>Reg Spencer</td>
<td>$1.71</td>
<td>$508</td>
<td>$8.20</td>
<td>$8.30</td>
<td>21%</td>
<td>0.50</td>
<td>Spec Buy</td>
<td>Spec Buy</td>
</tr>
<tr>
<td>RockTech Lithium</td>
<td>RCK-CA</td>
<td>Katie Lachapelle</td>
<td>$5.13</td>
<td>$637</td>
<td>$7.50</td>
<td>$7.00</td>
<td>-7%</td>
<td>0.73</td>
<td>Spec Buy</td>
<td>Hold</td>
</tr>
<tr>
<td>Prospect Resources</td>
<td>PSC-ASX</td>
<td>Tim Hoff</td>
<td>$0.86</td>
<td>$369</td>
<td>$1.12</td>
<td>$1.10</td>
<td>-2%</td>
<td>0.78</td>
<td>Spec Buy</td>
<td>Spec Buy</td>
</tr>
<tr>
<td>Lithium Power Intl</td>
<td>LPI-ASX</td>
<td>Reg Spencer</td>
<td>$0.67</td>
<td>$234</td>
<td>$0.55</td>
<td>$1.20</td>
<td>118%</td>
<td>0.56</td>
<td>Spec Buy</td>
<td>Spec Buy</td>
</tr>
<tr>
<td>Atlantic Lithium</td>
<td>ALL-LON</td>
<td>Sam Catalano</td>
<td>$0.35</td>
<td>£201</td>
<td>£0.45</td>
<td>£0.60</td>
<td>33%</td>
<td>0.58</td>
<td>Spec Buy</td>
<td>Spec Buy</td>
</tr>
</tbody>
</table>

Source: FactSet (prices as at 21 January 2022), Canaccord Genuity estimates

Demand

Final EU sales are pending but look like they will exceed 2m units for 2021, in line with our estimates (CGe 2.1m), while China sales of 3.1m exceeded our 2.9m estimate – in spite of our August revision. Overall, from major market data received to date, we estimate 2021 EV sales of 6.2m units (70% BEV), +103% YoY. Growth was driven by China (+149% YoY) and Europe (+57%), accounting for 85% of global deliveries.
We have revised our EV sales assumptions on a rebased 2021 result (major markets) and now model a 20% CAGR out to 2030. Following stronger-than-expected 2021 EV sales, we have increased our 2022 estimates by 26% to 9.5m units, with our 2022-25 EV sales forecasts on average increasing by 22% against our prior estimates. We now forecast global sales to increase to 16.8m units by 2025 (+44% vs prior CGe), and by 2030 we forecast 46m units (representing an estimated EV penetration rate of 24% and 46%, respectively).

**Lithium demand revisions**

Revisions to our EV sales forecasts result in an upward revision to our LCE demand forecasts by ~10% on average over the next five years, with nearer term estimates lifting by 10% (56kt LCE) and 8% (57kt) in 2022 and 2023, respectively. Our longer-term forecasts continue to call for LCE demand of ~1.2Mt in 2025 and ~2.5Mt by 2030, representing CAGR of 20% out to 2030.
Cathode costs a risk to demand

Across all battery materials raw material costs have been rising, not only lithium. Nickel was up 19% YoY, cobalt was up 106% YoY and manganese was also up 117% YoY. At current prices an NCM 622 cathode would be 138% more expensive based on the raw materials alone. LFP pricing has also risen strongly due to demand and lithium input costs (Figure 7) and is up 178% YoY. So even LFP cathodes, which there was a large positioning towards in 2021, will likely be facing cost pressures. It is worth noting that, on our calculations, LFP cathodes would have risen 199% in 2021 vs the 138% that NMC cathodes would have increased on a US$/kWh basis. However, based on these calculations, LFP is still 58% cheaper on a US$/kWh basis.

Supply

While elevated prices resulted in notable increases in production rates across the Western Australian spodumene producers and South American brine producers over 2021, supply failed to keep up with demand. We anticipated incentive pricing to begin around US$15k/t however prices did not hold there for long enough to test our thesis. We are now nearly 3x incentive pricing and on our estimates many marginal operations would be profitable at these levels. We anticipate a response from the major brine producers in the next two years which may help the market move towards balance. Only Core Lithium (CXO-ASX), Lithium Americas (LAC-CA), Sigma (SGML-TSX) and Argosy (AGY-ASX) are expected to add greenfields lithium units in 2022 (most of this will occur in Q4). We have updated our supply to include several Chinese brine operations which have been in the spotlight recently.
In our last update we noted that the majority of the planned development projects were owned by single asset companies, which in our view presented risks to lithium supply through a likely lack of adequate capital investment. Since then, we have seen industry consolidation, with larger, better capitalised companies (i.e. major diversified miners, large chemical companies, OEMs) buying or taking ownership in a number or advanced developers. The spot price has also resulted in higher market capitalisation, enabling access to equity. We now take the view that financing these projects is less of a risk in the current environment and model them in our supply.

Despite the financing of several lithium projects, we highlight our previous work (Plaid Acceleration) where we assessed company guidance for first production and ultimate name plate capacity vs what was actually achieved. On average, projects are delayed 6-18 months for construction and ramp up generally take longer than expected. We have shaped our production forecasts to take delays into account given the pool of expertise is limited and jurisdictions such as Western Australia are experiencing labour issues due to COVID-19.

Figure 9: Near-term LCE supply forecast changes

Source: Company reports, Canaccord Genuity estimates

Figure 10: Market supply forecast revisions

Source: Company reports, Canaccord Genuity estimates
**Market balance**

*Increasing our near-term market deficits*

Based on our revised demand and supply forecasts, our market balance forecasts have largely moved in lock step. Overall, demand is higher, however, a supply response is also occurring, in our view. This ultimately leads us to have more certainty that 2025-26 will represent a period of a market more in balance/small surplus. Figure 11 demonstrates this, particularly post 2025 where our deficits have shrunk.

We expect 2022 and 2023 to remain in deficit despite increasing supply from the continued high pace of sales. While chip shortages have impacted the market, CRU expects to see these begin to reduce in 2022 and we believe these chips will ultimately end up in EVs. Over this time period we would expect to see some supply response by some of the majors or brownfields producers such as PLS who can more easily increase output vs greenfields developers.

**Figure 11: Changes in market balance between forecasts**

In 2024 our previous market surplus has reverted to a deficit (albeit small). We could flex several assumptions to either develop small surpluses or deficits so currently it’s a ‘line ball’ which will depend on the delivery of tonnes.

Perhaps the largest change in our forecasts comes post 2025. Previously we anticipated incentive pricing of US$15k/t but there had not yet been the momentum in *project investment*. Given that we are now 3x our incentive price that and the fact we have seen increased investment being allocated to producing assets, we believe we can pencil in some of the expected production, although on delayed ramp-up timeframes.
**Figure 12: Lithium SxD model summary**

<table>
<thead>
<tr>
<th></th>
<th>2019a</th>
<th>2020a</th>
<th>2021e</th>
<th>2022e</th>
<th>2023e</th>
<th>2024e</th>
<th>2025e</th>
<th>2026e</th>
<th>2027e</th>
<th>2028e</th>
<th>2029e</th>
<th>2030e</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Supply</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brines</td>
<td>150</td>
<td>150</td>
<td>207</td>
<td>276</td>
<td>342</td>
<td>430</td>
<td>533</td>
<td>600</td>
<td>658</td>
<td>734</td>
<td>784</td>
<td>809</td>
</tr>
<tr>
<td>Hard rock mine prod’n</td>
<td>240</td>
<td>225</td>
<td>296</td>
<td>385</td>
<td>498</td>
<td>721</td>
<td>1008</td>
<td>1102</td>
<td>1135</td>
<td>1162</td>
<td>1165</td>
<td>1180</td>
</tr>
<tr>
<td>Effective converter capacity</td>
<td>156</td>
<td>195</td>
<td>257</td>
<td>328</td>
<td>442</td>
<td>566</td>
<td>723</td>
<td>901</td>
<td>984</td>
<td>1089</td>
<td>1146</td>
<td>1164</td>
</tr>
<tr>
<td><strong>Total market supply</strong></td>
<td>306</td>
<td>346</td>
<td>465</td>
<td>604</td>
<td>785</td>
<td>995</td>
<td>1257</td>
<td>1501</td>
<td>1642</td>
<td>1823</td>
<td>1930</td>
<td>1973</td>
</tr>
<tr>
<td>YoY change %</td>
<td>16%</td>
<td>13%</td>
<td>34%</td>
<td>30%</td>
<td>27%</td>
<td>26%</td>
<td>19%</td>
<td>9%</td>
<td>11%</td>
<td>6%</td>
<td>2%</td>
<td></td>
</tr>
</tbody>
</table>

|                  |       |       |       |       |       |       |       |       |       |       |       |       |
| **Demand**       |       |       |       |       |       |       |       |       |       |       |       |       |
| Industrial use   | 108   | 104   | 107   | 109   | 111   | 115   | 118   | 120   | 122   | 125   | 127   |       |
| Market share %   | 41%   | 34%   | 20%   | 17%   | 14%   | 11%   | 9%    | 8%    | 8%    | 6%    | 5%    | 5%    |
| Batteries - EV’s | 104   | 137   | 276   | 377   | 513   | 686   | 879   | 1122  | 1365  | 1614  | 1841  | 2015  |
| Batteries - other (inc WIP) | 16    | 28    | 117   | 109   | 132   | 162   | 185   | 225   | 243   | 270   | 293   | 313   |
| Total batteries  | 156   | 199   | 428   | 522   | 682   | 886   | 1104  | 1388  | 1650  | 1927  | 2179  | 2375  |
| Market share %   | 59%   | 68%   | 86%   | 83%   | 86%   | 89%   | 91%   | 92%   | 93%   | 95%   | 95%   | 95%   |
| **Total demand** | 264   | 304   | 535   | 631   | 793   | 999   | 1220  | 1506  | 1770  | 2049  | 2304  | 2502  |
| YoY change %     | 6%    | 15%   | 76%   | 18%   | 26%   | 26%   | 22%   | 23%   | 15%   | 16%   | 12%   | 9%    |

| Market surplus/(deficit) | 43   | 42   | -70  | -27  | -4   | -37  | -5   | -128 | -227 | -374 | -529 |
| %                        | 15%  | 14%  | -13% | -4%  | -1%  | 0%   | 3%   | -7%  | -11% | -16% | -21% |

Source: Company reports, Canaccord Genuity estimates

**Figure 13: The LCE market balance is close throughout the 2020’s until demand outstrips supply. It is likely projects exist but will require higher incentive prices to bring into production**

Source: Company reports, Canaccord Genuity estimates
Pricing – into the unknown

We adjusted pricing in September (Lithium prices go exponential) and were looking for all time high pricing. Since then, pricing has run even further than expected, with Chinese chemical pricing approaching US$50k/t in early January. We are now well beyond the horizon of pricing, in uncharted territory. Our industry contacts suggest this pricing is not just for marginal fringe participants who are short lithium but (with a lag) by all customers. How long it stays this high and ultimately how high it goes is anyone’s guess. We have heard of some auto makers talking of demand destruction at these levels and so how much more pain is absorbable may be limited from here.
Lithium price forecasts – records likely to be broken through 2022

We simply don’t know where the ultimate top will be. All we can look for is when pressure relief valves may kick in and, in our view, from the supply side this is not likely until later in SepQ’22/DecQ’22. As a result, we expect pricing to remain elevated.

We have adjusted our near-term price deck higher across all products to match the current trajectory but stop short from pushing pricing beyond US$55k/t. It may prove to be conservative (yet again), given we also forecast deficits in 2023 and 2024. We have taken the view, however, that as these deficits shrink and additional supply comes into the market fewer customers will ‘bid up’ pricing leading to a fall in pricing towards 2025. However, considering we are forecasting pricing of ~US$30k/t (where we thought pricing would peak in 2022) in 2023 we don’t think this will be overly impactful for our covered companies.

At US$50k/t pricing is ~3x our assumed ‘incentive price’. Ultimately this causes a supply response which we see hitting the market in 2025. The longer pricing stays at these levels the more likely our forecasted supply issues in 2026 and beyond will be solved. On our current forecast we expect a bottoming of prices in 2025 but have lifted our LT pricing from US$15k/t to US$17.5k/t on account of the rise in capital intensity we have seen for projects over the past two years. This follows that the Spodumene has been linked much closer to chemical pricing since the start of 2021 on converters maintaining a c.30% margin over the longer term. Figure 18: Converter margins unlikely to peak as high as the 2017 price excursion due to a lack of available SC6. In our view, the power ultimately captured by SC6 producers shows what spodumene pricing could be achieved at differing converter margins. Of note is the potential for converters to pay over US$5,000/t throughout 2022 if they accept 0% margins!

Figure 17: CGe previous vs new price deck

| Product Description | Price (US$/t) | 2021a | 2022e | Mar’22 | Apr’22 | May’22 | Jun’22 | Jul’22 | Aug’22 | Sep’22 | Oct’22 | Nov’22 | Dec’22 | 2023a | 2024a | 2025a | 2026a | 2027a | 2028a | 2029a | 2030a |
|---------------------|--------------|-------|-------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| OLD Lithium Hydroxide min 57% Li (US$/t Asia CIF) | 14250 | 15000 | 15000 | 14250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 |
| NEW Lithium Hydroxide min 57% Li (US$/t Asia CIF) | 14250 | 15000 | 15000 | 14250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 |
| OLD Lithium Hydroxide min 57% Li (US$/t China EXW) | 14250 | 15000 | 15000 | 14250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 |
| NEW Lithium Hydroxide min 57% Li (US$/t China EXW) | 14250 | 15000 | 15000 | 14250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 |
| OLD Lithium Hydroxide min 57% Li (US$/t FOB SWAm) | 14250 | 15000 | 15000 | 14250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 |
| NEW Lithium Hydroxide min 57% Li (US$/t FOB SWAm) | 14250 | 15000 | 15000 | 14250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 |
| OLD Lithium Carbonate min 99% Li (US$/t FOB SthAm) | 14250 | 15000 | 15000 | 14250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 |
| NEW Lithium Carbonate min 99% Li (US$/t FOB SthAm) | 14250 | 15000 | 15000 | 14250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 |
| OLD Lithium Carbonate min 99% Li (US$/t China EXW) | 14250 | 15000 | 15000 | 14250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 |
| NEW Lithium Carbonate min 99% Li (US$/t China EXW) | 14250 | 15000 | 15000 | 14250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 |
| OLD Spodumene Concentrate 6% Li2O (US$/t FOB) | 14250 | 15000 | 15000 | 14250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 |
| NEW Spodumene Concentrate 6% Li2O (US$/t FOB) | 14250 | 15000 | 15000 | 14250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 | 13250 | 13761 |

Source: Asian Metals, Canaccord Genuity estimates
Figure 18: Converter margins unlikely to peak as high as the 2017 price excursion due to a lack of available SC6. In our view, the power ultimately captured by SC6 producers.

Source: Asian Metals, Canaccord Genuity estimates

Our price forecast in September 2021 was quickly exceeded as pricing continued to push higher. As highlighted above we may be too conservative again if chemical prices are maintained at spot for any period of time.

Figure 19: Potential for converters to pay higher pricing for SC6 will depend on views

Source: Asian Metals, Canaccord Genuity estimates

Carbonate prices rallied in September/October before pausing into the end of the year before running again to catch up to Chinese chemical pricing.

Figure 20: Spodumene pricing and previous CGe forecasts

Source: Asian Metals, Canaccord Genuity estimates

Figure 21: Spodumene pricing and updated CGe forecasts

Source: Asian Metals, Canaccord Genuity estimates

Figure 22: South American lithium carbonate pricing and previous CGe forecasts

Source: Asian Metals, Canaccord Genuity estimates

Figure 23: South American lithium carbonate pricing and updated CGe forecasts

Source: Asian Metals, Canaccord Genuity estimates
Chinese pricing has set the price trend over the last four months driven, we believe, by high demand for LFP batteries. During the 2017 run up there was a large expectation for NMC chemistries to dominate the cathode. Over the past three years we have seen LFP arguably grow in market share which has likely resulted in stronger demand growth for carbonate over hydroxide. We think this persists while consumers seek lower cost cathodes.

Lithium hydroxide rose steadily through the DecQ’21 and then rallied strongly in January with the other lithium commodities. We anticipate this pricing series to lag the spodumene and Chinese carbonate pricing as it is largely influenced by longer term contracts.
CG Lithium sector coverage

Figure 28 outlines estimate revisions for producers on our updated lithium pricing assumptions. See Figure 2 for target price and rating changes. PLS and IGO both stand out in near-term earnings with both companies likely to lift EBITDA towards A$2bn in FY23. However, FY24 demonstrates IGO’s more diversified base with EBITDA of A$1.2bn while PLS’s EBITDA falls to A$0.9bn on our forecasts.

**Figure 28: CG lithium producer estimate revisions**

<table>
<thead>
<tr>
<th>EBITDA CHANGES</th>
<th>2022E</th>
<th>2023E</th>
<th>2024E</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGO A$M</td>
<td>$1,232</td>
<td>$706</td>
<td>75%</td>
</tr>
<tr>
<td>PLS A$M</td>
<td>$977</td>
<td>$676</td>
<td>45%</td>
</tr>
<tr>
<td>AKE US$M</td>
<td>$484</td>
<td>$317</td>
<td>53%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NPAT CHANGES</th>
<th>2022E</th>
<th>2023E</th>
<th>2024E</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGO A$M</td>
<td>716</td>
<td>$372</td>
<td>92%</td>
</tr>
<tr>
<td>PLS A$M</td>
<td>654</td>
<td>$438</td>
<td>49%</td>
</tr>
<tr>
<td>AKE US$M</td>
<td>344</td>
<td>$42</td>
<td>72%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FCF CHANGES</th>
<th>2022E</th>
<th>2023E</th>
<th>2024E</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGO A$M</td>
<td>-491</td>
<td>$345</td>
<td>-342%</td>
</tr>
<tr>
<td>PLS A$M</td>
<td>572</td>
<td>$374</td>
<td>53%</td>
</tr>
<tr>
<td>AKE US$M</td>
<td>301</td>
<td>$93</td>
<td>423%</td>
</tr>
</tbody>
</table>

Source: Canaccord Genuity estimates

Pilbara Minerals Ltd (PLS-ASX: A$3.56, mkt cap A$11,282m | HOLD (from Buy), TP A$3.90 (from A$2.70), Tim Hoff)

We have updated our model for our pricing scenario and accelerated our expansion scenario at the Pilgangoora operations. We have also updated our EV/EBITDA multiple to 13x from 15x on account of our view that we are closer to the top of pricing than the bottom. This has led to a 39% increase in our price target to A$3.90. PLS is arguably the most levered name to the current lithium market, with EBITDA and FCF growth, but arguably the equity is now pricing in much of this in. It is also the most concentrated exposures with one operation in one jurisdiction. WA is now facing cost pressures and will likely be impacted over the next six months from the spread of COVID-19, in our view.

Figure 29 and Figure 30 below show our previous production profile and our updated profile. PLS has the resource base to expand and should be expanding to capture market share, especially since new production will compete for its current marginal buyers. On our accelerated forecast PLS’s EBITDA still peaks in 2023E at A$1.9bn before falling in 2025E to A$531m.

As mentioned in the pricing section current spot pricing could encourage spodumene buyers to bid up pricing towards US$5,000/t which will likely result in further rallies in the stock price. Given the stock has rallied 76% over the last three months vs peers AKE (+20%) and IGO (+32%) we see the stock trading at fair value (0.95x P/NAV) but seek value in other names or entry points on pull-backs.0020
We have updated our model for our pricing scenario for lithium and nickel and have integrated the WSA assets on our view that the WSA deal proceeds. Like with PLS we have derated our lithium business multiple from 15x to 13x. This has led to a 36% increase in our price target to A$15.00. While less levered to lithium than PLS or AKE, we view IGO’s diversification and strategy as a strength to lever into battery materials and eventually downstream chemicals rather than simply lithium.

In December 2021, IGO announced that it had entered into a scheme of implementation with WSA to acquire all WSA all shares for A$3.36/share, which the WSA Board has recommended. On our updated price deck the acquisition appears well timed. IGO’s focus will be on the Odysseus mine; however, we believe there is optionality that may be unlocked by an owner with a larger balance sheet than WSA. Options in our view include expansion of the primary sulphide operation, potential large scale bulk underground mining to mine the Mt Goode and disseminated deposits and ultimately this to feed a downstream facility. For a business which previously lacked a pipeline of projects (other than early-stage exploration and Silver Knight), acquiring WSA gives IGO assets to optimise.

**Figure 31: Our SOTP valuation for IGO**

Source: Canaccord Genuity estimates

**IGO Limited (IGO-ASX: A$12.80, mkt cap A$10,110m | BUY, TP A$15.00 (from A$11.00), Tim Hoff)**

We have updated our model for our pricing scenario for lithium and nickel and have integrated the WSA assets on our view that the WSA deal proceeds. Like with PLS we have derated our lithium business multiple from 15x to 13x. This has led to a 36% increase in our price target to A$15.00. While less levered to lithium than PLS or AKE, we view IGO’s diversification and strategy as a strength to lever into battery materials and eventually downstream chemicals rather than simply lithium.

In December 2021, IGO announced that it had entered into a scheme of implementation with WSA to acquire all WSA all shares for A$3.36/share, which the WSA Board has recommended. On our updated price deck the acquisition appears well timed. IGO’s focus will be on the Odysseus mine; however, we believe there is optionality that may be unlocked by an owner with a larger balance sheet than WSA. Options in our view include expansion of the primary sulphide operation, potential large scale bulk underground mining to mine the Mt Goode and disseminated deposits and ultimately this to feed a downstream facility. For a business which previously lacked a pipeline of projects (other than early-stage exploration and Silver Knight), acquiring WSA gives IGO assets to optimise.

**Figure 31: Our SOTP valuation for IGO**

Source: Canaccord Genuity estimates
Allkem Limited (AKE-ASX: A$10.35, mkt cap A$7,070m | BUY, TP A$15.00 (from A$12.00), Reg Spencer)

AKE delivered a strong DecQ production result (see DecQ report – first look), with QoQ increases in carbonate output at Olaroz, and better than expected concentrate production from Mt Cattlin (including a CY21 production guidance beat). The outlook remains positive, with AKE pointing to continued pricing momentum in 2022, with priced for chemicals set to increase by 60% over DecQ averages in 1H’CY22, and 51% for concentrate, to US$2,500/t in the MarQ’22.

We expect the focus to begin to shift to delivery of AKE’s various growth projects, with Naraha LiOH scheduled for commissioning in 1H’22, Olaroz II expansion (2H CY22), FID for James Bay in 2H’CY22, while extended timelines for Sal De Vida (commissioning now expected 2HCY23 from 1HCY23) potentially offset by a possible increase in Stage 1 capacity to 15ktpa. AKE are expected to release a detailed plan for their growth projects (we expect this to include updated project timelines, additional capacity expansions such as Cauchari/Olaroz III/Sal de Vida II/Naraha II, and capital cost requirements) in the MarQ’22.

Specific model revisions relate primarily to Sal de Vida (increased stage 1 capacity to 15ktpa and pushed commissioning out to 2HCY23) and James Bay (minor changes to model assumptions following the feasibility study in December 2021, including revisions to our assumed downstream converter in Quebec – see James Bay feasibility study – first look).

Estimate revisions (outlined in Figure 28) relate primarily to our updated lithium price deck, with an average 41% increase in modelled EBITDA over FY21 E-23E. Our target price (blended NPV9% and 13x five-year forward average EBITDA) increases to A$15.00 from $12.00.

Lithium Americas Corp: (LAC-TSX: C$31.56, mkt cap C$4,028 | SPEC BUY, TP C$54.00 (from C$46.00), Katie Lachapelle)

Lithium Americas made considerable progress over the last 12 months. Construction continued at Cauchari-Olaroz, and the project remains on track for first production in mid-2022. We look forward to further details on a Stage 2 expansion to 60ktpa (+20ktpa, Stage 1 40ktpa LCE), which are expected in Q1 2022.

At Thacker Pass, LAC announced an updated M&I resource (+128%), and an increase in Phase 1 production capacity to 40ktpa LCE in the upcoming Feasibility Study. The FS is also expected to incorporate a potential Phase 2 expansion, which would double capacity to 80ktpa. The final design of the project will depend on the outcome of the strategic partnership process, which is ongoing. With respect to project permits, a court hearing on the appeal of the ROD is scheduled to take place in Q1 2022. We expect the appeal ruling to go in LAC’s favour. Early-works construction could start shortly thereafter. We forecast first production in 2025.

Another major potential catalyst for LAC, in our view, will be the completion of the acquisition of Millennial Lithium which is expected to close on 25 January. After the transaction closes, LAC plans to release more details on their development plan for Pastos Grandes. We expect this plan to be materially different than Millennial’s given the proximity of Pastos Grandes to Cauchari-Olaroz (~100km), and potential regional synergies.

We have updated our estimates to reflect our revised lithium price deck. As a result, our 12-month NAVPS has increased to C$53.88 (previously C$38.51), and we are increasing our target price to C$54.00, from C$46.00 previously. Our target price is based on 1.0x NAV, now measured as at 1 January 2023. Given the 61% implied return to our target, we maintain our SPEC BUY rating.
Liontown Resources (LTR-ASX: A$1.62, mkt cap A$3,801m | SPEC BUY, TP A$2.30 (from A$1.90), Reg Spencer)
LTR completed a DFS for Kathleen Valley in November 2021 (see Kathleen Valley DFS recap), and completed an A$450m placement (plus SPP) to fund initial Stage 1 development costs. Detailed engineering and design work is underway for the project, with LTR targeting the award of all key equipment packages over the next six months. First production from Stage 1 is scheduled for 2024.

LTR announced its first offtake agreement in January 2022 with major Li-ion battery producer LG Energy Solutions. Terms of the offtake include an initial five years (with option for additional five years), covering 100ktpa concentrate in Year 1, increasing to 150ktpa in subsequent years (vs Stage 1 capacity of >500ktpa SC). Pricing under the offtake is linked to LiOH chemical prices.

Our target price (risked NPV9%) for LTR increases to A$2.30 from A$1.90, reflecting updated lithium pricing assumptions, net of the capital raising and share issue.

Ioneer: (INR-ASX: A$0.74, mkt cap A$1,661m | HOLD (from Spec Buy), TP A$0.85 (from A$0.75), Tim Hoff)

We have updated our price target for INR after its successful placement to Sibanye-Stillwater and have normalised our discount rate to 8% (previously 7%), in line with our sector coverage.

2021 closed out a successful year for INR, signing an offtake agreement with EcoPro, securing a US$490m investment commitment from Sibanye-Stillwater for 50% of the project and raising c.A$175m in new equity. This leaves INR in a strong position to secure the remaining capital it requires to fund the plant. INR was invited to submit an application for a US DOE Loans Program which along with additional debt, we expect to fully fund the project.

Looking to 2022 INR will have a busy year of project preparation with the awarding of work modules, further offtake agreements and a listing on the US stock exchange. A key to the project timing remains permitting of the project by the BLM. This is likely to be delivered in the middle of the year and we expect there to be a strong focus on the Thiem’s Buckwheat. We believe INR has taken mitigating actions to avoid disturbance and enhance the protection of the (likely, in our view) potentially endangered plant. However, timing for the permits has been extended and while delays are likely to be used to further preparatory work, it ultimately pushes back cash flows.

With the stock performing well throughout 2021 and trading at 0.93x P/NAV we downgrade to a HOLD and look for better opportunities to enter the stock once permitting and timeline risks are resolved.

Standard Lithium Corp: (SLI-TSX: C$8.14, mkt cap C$1,311 | SPEC BUY, TP C$14.00 (unchanged), Katie Lachapelle)

SLI continues to advance work on its 20.9ktpa LCE direct lithium extraction project in South Arkansas. We anticipate a final investment decision on the project in Q4 2022, following the release of a Definitive Feasibility Study. The FS is already well underway. All resource data is complete, and management is now focused on optimization of the commercial scale plant using data from its demonstration plant (which has been operating on a 24/7 basis since May 2020).

The next major milestone will be the renegotiation and finalization of the terms of the joint venture with LANXESS. In our view, SLI is in a far better negotiating position than it was in 2018 when the JV Term Sheet was first signed. Lithium prices have improved dramatically and the company recently announced a US$100 million direct investment from Koch Strategic Platforms (note here). These funds (and Koch’s backing) could be used as negotiating tools to help increase SLI’s stake in the project – 70% LANXESS/30% SLI was previously proposed. Discussions are already underway, and management expects to provide an update in January 2022.
We view the recent pullback in SLI’s shares (-30% MoM) as a good buying opportunity ahead of a catalyst rich 2022. In addition to updated JV terms, we expect additional news on SLI’s development plans, Koch’s involvement in the project, and SLI’s strategy for its South-West Arkansas (SWA) project.

Our model has been revised to reflect our updated lithium price deck and recent share price performance. We’ve also assumed that SLI is successful in achieving all milestones required to increase its interest in the project to 40% (based on the previous non-binding JV terms). The company is now trading at 0.7x NAV, despite having historically traded at a premium to peers. Given recent volatility we have reduced our target multiple to 1.0x NAV to align with peers. As a result, our target price remains unchanged at $14.00 and we maintain our SPEC BUY rating.

**Vulcan Energy Resources (VUL-ASX: A$9.42, mkt cap A$1,316m | SPEC BUY, TP A$23.00 (from A$22.00), Tim Hoff)**

We think Vulcan remains one of the most compelling stories in the lithium sector from a valuation point of view and thematically, exposed to the European battery supply chain. We have updated our price deck and increased our discount rate to 9% to better align with our coverage universe. Vulcan is well funded to deliver its near-term ambitions of delivering the pilot plant, progressing engineering of the Central Lithium Plant and delivering a DFS. Our price target has increased by 5% to A$23.00 (0.42x P/NAV).

Vulcan had an outstanding 2021, delivering a PFS for its Zero Carbon Lithium project; aligning with DuPont to progress its DLE tech: signing five offtakes with LG Energy Solutions, Umicore, Renault, Stellantis and Volkswagen; raising c. A$320m in equity, and in early 2022 expanding its tenement holdings and signing an agreement with Nobian to study a joint development of the Central Lithium Plant amongst a few.

In 2022 Vulcan plans to progress geological studies on over the project areas, deliver its Phase 1 DFS and updated Phase 2 study, progress Phase 1 financing (a full offtake book will likely benefit VUL in our view), construct and commission a demonstration DLE plant and advance licence and permitting.

**Core Lithium (CXO-ASX: A$0.85, mkt cap A$1,532m | SPEC BUY, TP A$1.00 (from A$0.70), Tim Hoff)**

Core remains on track to progress the Finniss Lithium project in the Northern Territory in 2H’22. This represents one of the few greenfield sources of lithium (spodumene concentrate) available to the market in 2022. As outlined in our initiation, the DFS envisions a 175ktpa of SC6 operation mined over eight years at an AISC of US$441/t SC6. We have updated our pricing assumption and, given incentive pricing is in place, expanded production by 50% throughout the mine at a capex cost of A$30m leading to a 42% increase in our NAV to A$1.00/share (0.88x P/NAV).

CXO is fully financed to deliver the project and will continue its exploration program to delineate additional resources in 2022. We take the view that the Bynoe Pegmatite field has further upside for resource expansion and believe this is one of the keys to unlocking further value at CXO (Drills Ah Hoy!). Once a larger resource is delivered CXO has optionality to double capacity or develop a downstream processing facility which have previously flagged by management.

**Sigma Lithium Corp: (SGML-TSX: C$11.97, mkt cap C$1,121 | SPEC BUY, TP C$17.00 (from C$14.00), Katie Lachapelle)**

Sigma Lithium performed extremely well in 2021, returning 335%. Significant advancements were made on the company’s flagship project, Grota do Cirilo, including the commencement of early works and civil works construction on site. Initial production is on track for Q4 2022. Phase 1 and Phase 2 production are well supported by offtake agreements with Mitsui and LG Chem, the latter of which was signed in October 2021 (see our note here).
Before year-end the company successfully completed an upsized private placement of 11.6 million common shares priced at C$11.75/share. Gross proceeds of the transaction were C$136.7 million, C$64.2 million of which was invested by funds and accounts managed by BlackRock. The proceeds from the offering will fully-fund construction of Phase 1 and should help advance Phase 2 and Phase 3 of the project.

Sigma remains our top pick among North American listed peers. In our view, the company is uniquely positioned to capitalise on higher prices (spot SC6 $2,700/t vs. Phase 1 cash cost $342/t), as one of few developers that can actually reach production in 2022. We also see substantial exploration upside on Sigma's property. The company is currently completing a ~12,000m drill program with the goal of increasing mineral resources by at least 50%. We apply a nominal in-situ valuation for existing mineral resources that are not currently included in SGML’s mine plan.

Some key potential catalysts to look out in 2022 include the release of a Pre-Feasibility Study in Q1, exploration program results and additional offtake and/or financing agreements for Phase 2 and 3.

We have revised our estimates to reflect our updated lithium price deck and rolled forward our target NAV to 1 January 2023. As a result, our target price has increased 21% to C$17.00. Our revised target price is based on 1.0x NAV. SGML currently trades at 0.7x NAV; we anticipate a re-rate as the company defines additional resources on its property and transitions from a developer to a producer generating free cash flow. Given the 33% implied return to our target, we maintain our SPEC BUY rating.

Lake Resources (LKE-ASX: A$0.94, mkt cap A$1,228 | SPEC BUY, TP A$1.50 (from A$1.15), Reg Spencer)

Following the release of our initiation report in October (see Some fine Argentinian brine), LKE commenced Resource drilling at its Kachi lithium project in Argentina. Drilling at Kachi is targeting both infill (current Resource comprises 77% Inferred) to support the DFS (due 1H'22, now to include assessment of expansion of capacity to 50ktpa, in line with our base case assumptions), as well as target Resource increases to support the expanded production capacity. In addition to the work currently being completed at Kachi, LKE have also commenced drilling at its other 100% Olaroz, Cauchari and Paso projects to assess resource potential with results expected over 1H'22.

Looking into 2022 we expect project financing and offtake discussions to progress, with plenty of additional news flow on the horizon (drilling, updated studies). We also highlight the recent increase in M&A activity in the sector and point out that Kachi is one of the last few, independent (no offtake committed) brine projects left globally. In our view, this makes the project highly strategic.

We have updated our estimates to reflect our revised price deck and rolled forward our valuation. As a result, our target price increases to A$1.50 (from A$1.15), 55% above the current share price. Our SPEC BUY rating is maintained.

Piedmont Lithium (PLL-ASX: A$0.68, mkt cap A$1093m | SPEC BUY, TP A$1.55 (from A$1.35), Reg Spencer)

Piedmont has continued to make solid progress over recent months, releasing a DFS for its Carolina lithium project, while also advancing key permits. While the LiOH production profile of 30kt outlined in the DFS remains unchanged, the source of the spodumene fed to the Carolina convertor has been revised. The DFS now envisages an initial SC6 production target of 242kt over 11 years which will be sourced entirely from Ore reserves (18Mt) at the Carolina spodumene mine (prior 248kt over 20 years from inventory of 37Mt). The study incorporates additional LiOH production (+19 years) to be sourced from offtake rights of over >200ktpa SC6 through the JV with Atlantic Lithium on the Ewoya Project in Ghana, and the JV with Sayona Mining's (SYA-ASX | Not Rated) Authier/NAL development projects in Quebec, Canada. Over the 30-year life of the project, production is expected to average 30kt LiOH, which would see Piedmont rank as the largest LiOH project in North America.
While the project's capital intensity of US $33k/t is considerably higher than the US$28k/t peer average, we suspect inflationary pressures will likely see average industry capital intensities increase, with a 'catch-up' in capex/opex among peer projects (specifically those with older/obtaged studies).

Looking in to 2022 we expect permitting and approvals to be a key theme (mid-2022), with offtake and financing discussions to ramp up shortly after. We have revised our development scenario to align with that outlined with the DFS, and have updated our model to include the new price deck. As a result, our price target increased to A$1.55 with our SPEC BUY rating maintained.

**Neo Lithium Corp: (NLC-TSX: C$6.42, mkt cap C$907| HOLD, TP C$6.50, Katie Lachapelle)**

In October 2021, Neo Lithium announced that it had received an all-cash offer from Chinese mining giant, Zijin Mining (2899.HK | Not rated), to acquire all outstanding shares of NLC at a price of C$6.50/share, for total consideration of C$960 million. The transaction is expected to close the week of 27 January 2022. All approvals from the mining and environmental authorities of Catamarca Province, Argentina have been received. The company is waiting on final regulatory approval from China (one approval is pending). We maintain our HOLD rating and C$6.50 target price, which is in line with the acquisition price.

**Firefinch Resources (FFX-ASX: A$0.75, mkt cap A$931m | SPEC BUY, TP A$1.90 (from A$1.55), Reg Spencer / Paul Howard)**

Since the release of our **initiation** report in Sep'21, FFX has delivered an updated DFS for the Goulamina lithium project (which now sees an expanded production scenario up to 800kt/a SC6 from ~430ktpa - see DFS recap) and in early January 2022 committed to project development with an FID (see **Goulamina FID**).

At Morilla, gold production is expected to ramp up over CY22 with mining was achieved during the DecQ (see here), and exploration drilling has uncovered a new high-grade zone on the eastern side of the Morila Super Pit in Mal, which we believe will add additional ounces outside the current resource.

FFX also recently completed a placement and SPP at A$0.67/share. Gross proceeds of the transaction were A$100m with proceeds committed to lifting gold production at Morilla and accelerate exploration at Goulamina.

We have revised our estimates to reflect our updated lithium price deck and have rolled forward our model. As a result, our price target increases to A$1.90. We note the recent ECOWAS sanctions placed on Mali which has put downward pressure on the stock over the last week, however operations at Morilla remains unaffected, while the Leo Lithium (Goulamina) demerger remains scheduled for MarQ’22. We maintain our SPEC BUY rating.

**Galan Lithium Limited: (GLN-ASX: A$1.71, mkt cap A$546m | SPEC BUY, TP A$3.40 (from A$2.80), Reg Spencer)**

Galan continues to make progress at both its Hombre Muerto West and Candelas Lithium projects. As a recap, GLN completed a PEA for HMW in 2020 which outlined a 40-year 20kt/a Li2CO3 operation with capex/opex of US$439m and ~US$4,000/t respectively (see recent initiation here). Resource drilling, brine flow testing and permitting discussions (potential for LiCl concentrate production) are underway, with results expected in the 1H’2022.

At Candelas, GLN recently released the outcomes of a PEA (see Candelas recap) which combined with HMW represents possible combined production capacity of ~35kt/a LCE across both projects. Work at Candelas to optimise areas of the project are currently underway, with a focus on the location of the evaporation ponds. Results received over the coming months will likely put GLN in a position to firm up a development strategy for Candelas and HMW, which in our view presents as a potential re-rating event.
After updating our model to incorporate our most recent price deck, and rolling forward our model, our target price increases by 21% to A$3.40.

**Rock Tech Lithium: (RCK-TSX: C$5.13, mkt cap C$367) SPEC BUY (from Hold), TP C$7.00 (from C$7.50), Katie Lachapelle)**

We initiated coverage of Rock Tech in October 2021. Since our launch, the company completed an engineering study on the construction and operation of its proposed lithium hydroxide converter in Germany. The study outlined an initial capital cost of €462 million for a 24kt per annum converter that is expected to produce lithium hydroxide at an average LOM operating cost of ~US$8,427/t. A site has already been secured for the converter in Brandenburg Germany, a 90-minute drive from Tesla’s Berlin Gigafactory. The company’s long-term goal is to build and operate four of these conversion plants in Germany by 2030, to capitalise on booming EV sales in Europe. We view this buildout as ambitious, and only model one conversion plant at this time.

Several project development milestones need to be achieved in 2022, to meet management’s projected timeline of first production in 2024. These include: a Pre-Feasibility Study (Q1 2022), awarding of an EPCM contract, ordering of long lead time items, a strategic partnership agreement (H1 2022), and a complete project financing package (H1 2022). To be conservative, our model continues to assume a one-year delay with first production in 2025.

We have revised our model to reflect our updated lithium price deck and recent share price performance (-25% since our last update). Our future equity raises now occur at the current share price, which offsets the rise in our price deck. As a result, we are modestly reducing our target price to C$7.00 (previously C$7.50). Our target price is based on 1.0x NAV measured as at 1 January 2023. Given the recent pullback in the shares, and the 36% implied return to our target we are upgrading RCK to SPEC BUY (from Hold).

**Prospect Resources (PSC-ASX: A$0.86, mkt cap A$369m | SPEC BUY, TP A$1.10 (from A$1.12), Tim Hoff)**

In December 2021, PSC announced that it had received an all-cash offer from Chinese mining company, Huayou cobalt (603799.SHA | Not rated), to acquire 100% of the Arcadia project from PSC and its minority shareholder for US$422m (A$590m). PSC has highlighted it intends to retain up to US$50m for investment in other projects and return the remainder (c.A$0.90/share on our estimates) to shareholders.

PSC anticipates the transaction to close in late MarQ/early JunQ 2022, pending the successful completion of conditions precedent (see Lithium Santa has one more gift for 2021 for list of conditions).

The company has released that it will settle an offtake break fee for US$8m. We have now taken this into account and forecast US$30m in capital gains tax and A$20m in selling costs in our valuation. This has led to a minor revision of our target price down to A$1.10, see Figure 32 for our SOTP. Maintain SPEC BUY, 0.77x P/NAV (17.5% below cash backing!).

**Figure 32: Our basic SOTP**

<table>
<thead>
<tr>
<th>DecQ ’22</th>
<th>A$m</th>
<th>RISK ADJ. EQUITY</th>
<th>A$m PER SHARE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exploration</td>
<td>30</td>
<td>30</td>
<td>$0.06</td>
</tr>
<tr>
<td>Cash distribution</td>
<td>422</td>
<td>422</td>
<td>$0.90</td>
</tr>
<tr>
<td>Net Cash</td>
<td>62</td>
<td>62</td>
<td>$0.13</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>514</strong></td>
<td></td>
<td><strong>$1.10</strong></td>
</tr>
<tr>
<td><strong>Price target</strong></td>
<td></td>
<td></td>
<td><strong>$1.10</strong></td>
</tr>
</tbody>
</table>

Source: Company reports, Canaccord Genuity estimates
Lithium Power International (LPI-ASX: A$0.67, mkt cap A$255m | SPEC BUY, TP A$1.20 (from A$0.55), Reg Spencer)

LPI is nearing an FID for the 52% owned Maricunga brine project in Chile after recently releasing an updated DFS (see Updated Maricunga DFS – first look). The DFS outlined an initial, 20-year, 15.2ktpa brine project, with capex/opex of US$626m (inc. US$62m contingency) and US$3,718/t, respectively. The study is based on Resources hosted within the permitted ‘Old Code’ concessions (1.9Mt at 951ppm Li); however, we note an additional 1Mt are hosted within ‘New Code’ defined to depths of only 200m. Additionally, LPI has outlined an exploration target of 1.2-2.1Mt LCE within the project area. Subject to further drilling, increased Resources could ultimately support a ‘Stage 2’ expansion of planned production/capacity to ~30ktpa LCE, in our view.

Looking forward, LPI will update EPC proposals (Q1’22) ahead of the FID expected at the back end of 2022. Subject to funding, LPI could commence construction in 2022 and achieve first production in late 2024.

We have increased our project capex and made minor revisions to our production model to align with the recent DFS. Updated lithium pricing assumptions and adjusted project risk weighting (80% from 55%, reflecting de-risking on completion of the updated DFS) sees our target price (risked NPV10%) increase to A$1.20.

Atlantic Lithium (ALL-AIM: 35p, mkt cap £201m | SPEC BUY, TP 60p (from 45p), Sam Catalano)

Based on scoping study outcomes for a ~300ktpa SC6 operation, we estimate that Ewoyaa is both the lowest opex (~US$230/t, plus ~US$18/t in SIB) and lowest capex intensity (~US$238/t) spodumene project available for development globally. We see the next key potential catalyst as the release of a PFS study, expected ~end-1Q22. Further we note that Atlantic has ~US$20m of cash (and no debt), in addition to being fully-funded to production through its agreement with Piedmont Lithium (Piedmont has agreed to an earn-in agreement which will see it fully fund regional exploration, feasibility studies and construction of Ewoyaa in a total commitment of ~US$102m).

In addition to PLL’s group level holding (~10%), it will also take a 50% interest in both the project and spodumene offtake. We believe a key point of differentiation to many peers will be the release of a positive PFS during 1H22, but with no subsequent capital call required for further study or development. We expect ongoing positive exploration news flow (we note the recent ~50% increase to the resource base, which supports a ~11-12-year mine life). Within the context of a very active M&A backdrop within the Lithium sector, we note that ALLA retains control over 50% of offtake, maintains control and operatorship of the asset, and PLL holds no pre-emptive options over ALLA’s 50% of the asset and offtake.

With the European market less familiar with primary Lithium producers that some other regional markets, we believe that ALLA trades at a discount to peers on a consistent P/NAV basis, accordingly our TP is reached by aligning with trading levels of global peers. Today’s lithium deck changes see us upgrade our ALLA NPV to 45p/share (from 35p/share) and target price to 60p (based on a consistent 1.3x NPV to align with global peers – see initiation for further details on target price methodology).
Appendix: Important Disclosures

For the purposes of UK regulation Canaccord Genuity Limited produces non-independent research which is a marketing communication under the Financial Conduct Authority (FCA) Conduct of Business Rules and an investment recommendation under the Market Abuse Regulation and is not prepared in accordance with legal requirements designed to promote the independence of investment research, nor is it subject to any prohibition on dealing ahead of the dissemination of investment research. However, Canaccord Genuity Limited does have procedures in place to identify and manage conflicts of interest which may arise in the production of non-independent research, which include preventing dealing ahead and Information Barrier procedures. Further detail on Canaccord Genuity Limited’s conflict management policies can be accessed at the following website (provided as a hyperlink if this report is being read electronically): http://www.canaccordgenuity.com/en/cm/SiteInformation/Disclaimer/UK-Disclosures/.

Analyst Certification

Each authoring analyst of Canaccord Genuity whose name appears on the front page of this research hereby certifies that (i) the recommendations and opinions expressed in this research accurately reflect the authoring analyst’s personal, independent and objective views about any and all of the designated investments or relevant issuers discussed herein that are within such authoring analyst’s coverage universe and (ii) no part of the authoring analyst’s compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in the research, and (iii) to the best of the authoring analyst’s knowledge, she/he is not in receipt of material non-public information about the issuer.

Analysts employed outside the US are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity LLC and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Sector Coverage

Individuals identified as “Sector Coverage” cover a subject company’s industry in the identified jurisdiction, but are not authoring analysts of the report.

Investment Recommendation

Date and time of first dissemination: January 24, 2022, 01:09 ET
Date and time of production: January 24, 2022, 01:09 ET

Compendium Report

This report covers six or more subject companies and therefore is a compendium report and Canaccord Genuity and its affiliated companies hereby direct the reader to the specific disclosures related to the subject companies discussed in this report, which may be obtained at the following website (provided as a hyperlink if this report is being read electronically) http://disclosures.canaccordgenuity.com/EN/Pages/default.aspx; or by sending a request to Canaccord Genuity Corp. Research, Attn: Disclosures, P.O. Box 10337 Pacific Centre, 2200-609 Granville Street, Vancouver, BC, Canada V7Y 1H2; or by sending a request by email to disclosures@cgf.com. The reader may also obtain a copy of Canaccord Genuity’s policies and procedures regarding the dissemination of research by following the steps outlined above.

Past performance

In line with Article 44(4)(b), MiFID II Delegated Regulation, we disclose price performance for the preceding five years or the whole period for which the financial instrument has been offered or investment service provided where less than five years. Please note price history refers to actual past performance, and that past performance is not a reliable indicator of future price and/or performance.

Distribution of Ratings:

Global Stock Ratings (as of 01/24/22)

<table>
<thead>
<tr>
<th>Rating</th>
<th>Coverage Universe</th>
<th>IB Clients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>#</td>
<td>%</td>
</tr>
<tr>
<td>Buy</td>
<td>663</td>
<td>69.28%</td>
</tr>
<tr>
<td>Hold</td>
<td>132</td>
<td>13.79%</td>
</tr>
<tr>
<td>Sell</td>
<td>8</td>
<td>0.84%</td>
</tr>
<tr>
<td>Speculative Buy</td>
<td>151</td>
<td>15.78%</td>
</tr>
</tbody>
</table>

*Total includes stocks that are Under Review

Canaccord Genuity Ratings System

BUY: The stock is expected to generate risk-adjusted returns of over 10% during the next 12 months.

HOLD: The stock is expected to generate risk-adjusted returns of 0-10% during the next 12 months.

SELL: The stock is expected to generate negative risk-adjusted returns during the next 12 months.
NOT RATED: Canaccord Genuity does not provide research coverage of the relevant issuer. “Risk-adjusted return” refers to the expected return in relation to the amount of risk associated with the designated investment or the relevant issuer.

Risk Qualifier

SPECULATIVE: Stocks bear significantly higher risk that typically cannot be valued by normal fundamental criteria. Investments in the stock may result in material loss.

12-Month Recommendation History (as of date same as the Global Stock Ratings table)

A list of all the recommendations on any issuer under coverage that was disseminated during the preceding 12-month period may be obtained at the following website (provided as a hyperlink if this report is being read electronically) http://disclosures-mar.canaccordgenuity.com/EN/Pages/default.aspx

Required Company-Specific Disclosures (as of date of this publication)

General Disclaimers

See “Required Company-Specific Disclosures” above for any of the following disclosures required as to companies referred to in this report: manager or co-manager roles; 1% or other ownership; compensation for certain services; types of client relationships; research analyst conflicts; managed/co-managed public offerings in prior periods; directorships; market making in equity securities and related derivatives. For reports identified above as compendium reports, the foregoing required company-specific disclosures can be found in a hyperlink located in the section labeled, “Compendium Reports.” “Canaccord Genuity” is the business name used by certain wholly owned subsidiaries of Canaccord Genuity Group Inc., including Canaccord Genuity LLC, Canaccord Genuity Limited, Canaccord Genuity Corp., and Canaccord Genuity (Australia) Limited, an affiliated company that is 80% owned by Canaccord Genuity Group Inc.

The authoring analysts who are responsible for the preparation of this research are employed by Canaccord Genuity Limited, which is authorised and regulated by the Financial Conduct Authority (FCA), Canaccord Genuity Corp., which is registered and regulated by the Investment Industry Regulatory Organization of Canada (IIROC) and Canaccord Genuity (Australia) Limited, which is authorized and regulated by ASIC.

With respect to research recommendations on issuers covered by a research analyst employed by Canaccord Genuity Limited, it is Canaccord Genuity Limited’s policy that research analysts publish financial estimates, valuations, price targets and recommendations for all companies covered at least every six months and as soon as possible after all relevant events.

The authoring analysts who are responsible for the preparation of this research have received (or will receive) compensation based upon (among other factors) the Investment Banking revenues and general profits of Canaccord Genuity. However, such authoring analysts have not received, and will not receive, compensation that is directly based upon or linked to one or more specific Investment Banking activities, or to recommendations contained in the research.

The information contained in this research has been compiled by Canaccord Genuity from sources believed to be reliable, but (with the exception of the information about Canaccord Genuity) no representation or warranty, express or implied, is made by Canaccord Genuity, its affiliated companies or any other person as to its fairness, accuracy, completeness or correctness. Canaccord Genuity, its affiliated companies or any other person as to its fairness, accuracy, completeness or correctness. Canaccord Genuity, its affiliated companies or any other person accepts any liability whatsoever for any direct or consequential loss arising from or relating to any use of the information contained in this research.

From time to time, Canaccord Genuity salespeople, traders, and other professionals provide oral or written market commentary or trading strategies to our clients and our principal trading desk that reflect opinions that are contrary to the opinions expressed in this research. Canaccord Genuity’s affiliates, principal trading desk, and investing businesses also from time to time make investment decisions that are inconsistent with the recommendations or views expressed in this research.

This research is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any designated investments discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the designated investments discussed in this research may not be eligible for sale in some jurisdictions. This research is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for general circulation to clients and does not have regard to the investment objectives, financial situation or particular needs of any particular person. Investors should obtain advice based on their own individual circumstances before making an investment decision. To the fullest extent permitted by law, none of Canaccord Genuity Limited, its affiliated companies or any other person accepts any liability whatsoever for any direct or consequential loss arising from or relating to any use of the information contained in this research.

Research Distribution Policy

Canaccord Genuity research is posted on the Canaccord Genuity Research Portal and will be available simultaneously for access by all of Canaccord Genuity’s customers who are entitled to receive the firm’s research. In addition research may be distributed by the firm’s sales and trading personnel via email, instant message or other electronic means. Customers entitled to receive research may also receive it via third party vendors. Until such time as research is made available to Canaccord Genuity’s customers as described above, Authoring Analysts will not discuss the contents of their research with Sales and Trading or Investment Banking employees without prior compliance consent.

24 January 2022
For further information about the proprietary model(s) associated with the covered issuer(s) in this research report, clients should contact their local sales representative.

**Short-Term Trade Ideas**

Research Analysts may, from time to time, discuss "short-term trade ideas" in research reports. A short-term trade idea offers a near-term view on how a security may trade, based on market and trading events or catalysts, and the resulting trading opportunity that may be available. Any such trading strategies are distinct from and do not affect the analysts' fundamental equity rating for such stocks. A short-term trade idea may differ from the price targets and recommendations in our published research reports that reflect the research analyst's views of the longer-term (i.e. one-year or greater) prospects of the subject company, as a result of the differing time horizons, methodologies and/or other factors. It is possible, for example, that a subject company's common equity that is considered a long-term 'Hold' or 'Sell' might present a short-term buying opportunity as a result of temporary selling pressure in the market or for other reasons described in the research report; conversely, a subject company's stock rated a long-term 'Buy' or "Speculative Buy' could be considered susceptible to a downward price correction, or other factors may exist that lead the research analyst to suggest a sale over the short-term. Short-term trade ideas are not ratings, nor are they part of any ratings system, and the firm does not intend, and does not undertake any obligation, to maintain or update short-term trade ideas. Short-term trade ideas are not suitable for all investors and are not tailored to individual investor circumstances and objectives, and investors should make their own independent decisions regarding any securities or strategies discussed herein. Please contact your salesperson for more information regarding Canaccord Genuity's research.

**For Canadian Residents:**

This research has been approved by Canaccord Genuity Corp., which accepts sole responsibility for this research and its dissemination in Canada. Canaccord Genuity Corp. is registered and regulated by the Investment Industry Regulatory Organization of Canada (IIROC) and is a Member of the Canadian Investor Protection Fund. Canadian clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity Corp. in their particular province or territory.

**For United Kingdom and European Residents:**

This research is for persons who are Eligible Counterparties or Professional Clients only and is exempt from the general restrictions in section 21 of the Financial Services and Markets Act 2000 (or any analogous legislation) on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the United Kingdom only to persons of a kind described in Article 19(5) (Investment Professionals) and 49(2) (High Net Worth companies, unincorporated associations etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. This material is not for distribution in the United Kingdom or Europe to retail clients, as defined under the rules of the Financial Conduct Authority.

**For United States Persons:**

Canaccord Genuity LLC, a US registered broker-dealer, accepts responsibility for this research and its dissemination in the United States. This research is intended for distribution in the United States only to certain US institutional investors. US clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity LLC. Analysts employed outside the US, as specifically indicated elsewhere in this report, are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity LLC and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

**For Jersey, Guernsey and Isle of Man Residents:**

This research is sent to you by Canaccord Genuity Wealth (International) Limited ("CGWI") for information purposes and is not to be construed as a solicitation or an offer to purchase or sell investments or related financial instruments. This research has been produced by an affiliate of CGWI for circulation to its institutional clients and also CGWI. Its contents have been approved by CGWI and we are providing it to you on the basis that we believe it to be of interest to you. This statement should be read in conjunction with your client agreement, CGWI's current terms of business and the other disclosures and disclaimers contained within this research. If you are in any doubt, you should consult your financial adviser.

CGWI is licensed and regulated by the Guernsey Financial Services Commission, the Jersey Financial Services Commission and the Isle of Man Financial Supervision Commission. CGWI is registered in Guernsey and is a wholly owned subsidiary of Canaccord Genuity Group Inc.

**For Australian Residents:**

This research is distributed in Australia by Canaccord Genuity Limited. Under ASIC Class Order (CO 03/1099), Canaccord Genuity Limited is exempt from the requirement to hold an Australian financial services licence for the provision of its financial services to you. Canaccord Genuity Limited is authorised and regulated by the Financial Conduct Authority under the laws of the United Kingdom which differ from Australian laws. This research is provided to you on the basis that you are a 'wholesale client' within the meaning of section 761G of the Corporations Act 2001 (Cth). To the extent that this research contains any advice, this is limited to general advice only. Recipients should take into account their own personal circumstances before making an investment decision. Clients wishing to effect any transactions in any financial products discussed in this research should do so through a qualified representative of Canaccord Genuity (Australia) Limited or its Wealth Management affiliated company, Canaccord Genuity Financial Limited ABN 69 008 896 311 holder of AFS Licence No 239052.

**For Hong Kong Residents:**